Indapta Therapeutics is a leading biotechnology company specializing in the development and commercialization of advanced cancer treatments. Their proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy offers a promising solution for various types of cancer. Indapta harnesses the natural power of the immune system to combat hematologic and solid tumors using their universal natural killer (NK) cell platform derived from healthy donors.

The company's allogeneic platform utilizes a subset of NK cells that are deficient in the FceR1g protein, known as g-NK cells. These cells exhibit exceptional efficacy in killing cancer cells, particularly when combined with monoclonal antibodies. By developing an off-the-shelf cellular therapy, Indapta eliminates the need for patient-specific treatments.

Their G-NK cell therapy is combined with FDA-approved tumor-targeting antibodies, providing a comprehensive and effective solution for cancer patients. With a dedicated team of experts, partnerships with notable collaborators, and a robust network of investors, Indapta is at the forefront of revolutionizing cancer treatment. Headquartered in Houston, TX, and Seattle, WA, Indapta is committed to addressing the limitations of currently available immunotherapies and improving outcomes for cancer patients worldwide